EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis

Katrijn Daenen iD, Anders Boyd iD, Virgil A S H Dalm, Jilske A Huijben, Sara C M Stoof iD, Lieuwe D J Bos, Diederik Gommers iD, Janke Schinkel, Eric C M van Gorp, Henrik Endeman

Immunity, Inflammation and Disease · 2026-04 · 14 (4)

DOI: 10.1002/iid3.70427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 26.04.2026. Verfasst von Katrijn Daenen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Respiratory Distress Syndrome, COVID-19 Drug Treatment, COVID-19, Adrenal Cortex Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment guidelines for acute respiratory distress syndrome (ARDS) recommend the use of high‐dose corticosteroids based on their anti‐inflammatory effects, yet the efficacy of this therapeutic strategy in patients with COVID‐19 related ARDS is inconclusive. To more thoroughly understand the mechanism of action for high‐dose corticosteroids in patients with COVID‐19‐related ARDS, we hypothesized that the reduction of inflammatory markers induced by high‐dose corticosteroids would reduce mortality (i.e., inflammation as a mediator). Design and Methods In this retrospective cohort study, we included patients with COVID‐19‐related ARDS admitted to the intensive care unit (ICU) of an academic hospital in Rotterdam, the Netherlands between March 2020 and June 2022. High‐dose corticosteroids were defined as > 6 mg of dexamethasone/day or equivalent. Biomarkers included C‐reactive protein (CRP), d ‐dimer, ferritin, leukocyte count, interleukin‐6 (IL‐6), lactate dehydrogenase, and neutrophil‐to‐lymphocyte ratio (NLR). Using a causal mediation framework, we estimated the average mediation effect (AME) and % mediation for each biomarker, allowing to quantify the degree to which continuous levels of inflammatory markers mediate the association between receiving high‐dose corticosteroids and mortality. The models used in this framework accounted for time‐varying treatment/mediation with inverse probability of treatment weights, determined from the covariates PaO 2 /FiO 2 ratio, sex at birth, age, NLR, and ICU length of stay.

Results

Of the 327 patients included, 122 (37.3%) received high‐dose corticosteroids. The risk of death was higher in patients who did vs. did not receive high‐dose corticosteroids [incidence rate = 0.54, 95% confidence interval (CI) = 0.42–0.71 and 0.21, 95% CI = 0.15–0.29/person‐month, respectively; p < 0.001]. This effect remained in most analyses accounting for time‐varying treatment/mediation. The association between high‐dose corticosteroids and mortality was reduced (i.e., mediated) with lower levels of CRP (AME = −0.006, 95% CI = −0.011, −0.002; %‐mediation = −82.0%), d ‐dimer (AME = −0.002, 95% CI = −0.005, −0.001; %‐mediation = −33.1%), and IL‐6 (AME = −0.002, 95% CI = −0.004, −0.001; %‐mediation = −25.5%). There was no evidence of mediation for other biomarkers.

Conclusion

CRP, d ‐dimer, and IL‐6 mediated the association between high‐dose corticosteroids and mortality. When inflammation was reduced, the deleterious effect of high‐dose corticosteroids was eliminated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Distress SyndromeCOVID-19 Drug TreatmentCOVID-19Adrenal Cortex HormonesAnti-Inflammatory AgentsHumansBiomarkersFemaleMaleRetrospective StudiesMiddle AgedAgedC-Reactive ProteinSARS-CoV-2Interleukin-6Mediation AnalysisFibrin Fibrinogen Degradation ProductsInflammationDexamethasoneIntensive Care UnitsL-Lactate Dehydrogenase

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2biomarkerinflammationmediation

Substanzen

BiomarkersAdrenal Cortex HormonesC-Reactive ProteinInterleukin-6fibrin fragment DFibrin Fibrinogen Degradation ProductsDexamethasoneAnti-Inflammatory AgentsL-Lactate Dehydrogenase

Autor:innen und Institutionen

  • Department of Intensive Care, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Stichting HIV Monitoring, Amsterdam, the Netherlands.
  • Infectious Diseases, Amsterdam University Medical Centers, Amsterdam Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.

ORCID-Profile: Katrijn Daenen, Anders Boyd, Sara C M Stoof, Diederik Gommers

Förderung

  • ZonMw

Zitieren

APA

Daenen, K., Boyd, A., Dalm, V. A. S. H., Huijben, J. A., Stoof, S. C. M., Bos, L. D. J., Gommers, D., Schinkel, J., van Gorp, E. C. M., & Endeman, H. (2026). Inflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis. Immunity, Inflammation and Disease, 14(4). https://doi.org/10.1002/iid3.70427

Vancouver

Daenen K, Boyd A, Dalm VASH, Huijben JA, Stoof SCM, Bos LDJ, et al. Inflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis. Immunity, Inflammation and Disease. 2026;14(4). doi:10.1002/iid3.70427

BibTeX
@article{Daenen2026,
  author = {Daenen, Katrijn and Boyd, Anders and Dalm, Virgil A S H and Huijben, Jilske A and Stoof, Sara C M and Bos, Lieuwe D J and Gommers, Diederik and Schinkel, Janke and van Gorp, Eric C M and Endeman, Henrik},
  title = {Inflammatory Biomarkers as Mediators of the Effect Between High‐Dose Corticosteroid Therapy and Mortality in COVID‐19‐Related ARDS: A Causal Mediation Analysis},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/iid3.70427}
}
Kostenlos starten →